
- /
- Supported exchanges
- / HM
- / RHO5.HM
ROCHE HLDG DR (RHO5 HM) stock market data APIs
ROCHE HLDG DR Financial Data Overview
There is no Profile data available for RHO5.HM.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ROCHE HLDG DR data using free add-ons & libraries
Get ROCHE HLDG DR Fundamental Data
ROCHE HLDG DR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR News

Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience
The integration of Accu-Chek SmartGuide's AI-enabled predictive CGM with the popular mySugr app delivers a simple, intuitive solution for people to manage their diabetes with greater ease. Accu-Chek S...


Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Shares of clinical-stage biotech Monte Rosa Therapeutics GLUE rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis NVS to develop novel molecula...

Drug developer Dualitas launches $65 million funding round
By Siddhi Mahatole (Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-...

Fosun's Henlius in talks with Johnson & Johnson, Roche on cancer drug
Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.